Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection

Long-term complications from coronavirus disease 2019 (COVID-19) are concerning, as survivors can develop subclinical multiorgan dysfunction. It is unknown if such complications are due to prolonged inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination may reduce...

Full description

Saved in:
Bibliographic Details
Main Authors: Fong, Siew-Wai, Goh, Yun Shan, Torres-Ruesta, Anthony, Chang, Zi Wei, Chan, Yi-Hao, Neo, Vanessa Kexin, Lee, Bernett, Duan, Kaibo, Amrun, Siti Naqiah, Yeo, Nicholas Kim-Wah, Chen, Hsiuyi V., Tay, Matthew Zirui, Carissimo, Guillaume, Tan, Seow Yen, Leo, Yee Sin, Lye, David C., Renia, Laurent, Young, Barnaby Edward, Ng, Lisa F. P.
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2023
Subjects:
Online Access:https://hdl.handle.net/10356/172157
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-172157
record_format dspace
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Science::Medicine
Biomarkers
COVID Vaccine
spellingShingle Science::Medicine
Biomarkers
COVID Vaccine
Fong, Siew-Wai
Goh, Yun Shan
Torres-Ruesta, Anthony
Chang, Zi Wei
Chan, Yi-Hao
Neo, Vanessa Kexin
Lee, Bernett
Duan, Kaibo
Amrun, Siti Naqiah
Yeo, Nicholas Kim-Wah
Chen, Hsiuyi V.
Tay, Matthew Zirui
Carissimo, Guillaume
Tan, Seow Yen
Leo, Yee Sin
Lye, David C.
Renia, Laurent
Young, Barnaby Edward
Ng, Lisa F. P.
Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection
description Long-term complications from coronavirus disease 2019 (COVID-19) are concerning, as survivors can develop subclinical multiorgan dysfunction. It is unknown if such complications are due to prolonged inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination may reduce sequela. We conducted a prospective longitudinal study on hospitalized patients over 24 months. Clinical symptoms were collected by self-reporting during follow-up, along with blood samples for quantification of inflammatory markers and immune cell frequencies. All patients were given one dose of mRNA vaccine at 12-16 months. Their immune profiles at 12 and 24 months were compared. Approximately 37% and 39% of our patients reported post-COVID-19 symptoms at 12 and 24 months, respectively. The proportion of symptomatic patients with more than one symptom decreased from 69% at 12 months to 56% at 24 months. Longitudinal cytokine profiling revealed a cluster of individuals with persistently high inflammatory cytokine levels 12 months after infection. Patients with prolonged inflammation showed elevated terminally differentiated memory T cells in their blood; 54% had symptoms at 12 months. The majority of inflammatory markers and dysregulated immune cells in vaccinated patients recovered to a healthy baseline at 24 months, even though symptoms persisted. Post-COVID-19 symptoms can linger for 2 years after the initial infection and are associated with prolonged inflammation. Prolonged inflammation in hospitalized patients resolves after 2 years. We define a set of analytes associated with persistent inflammation and presence of symptoms, which could be useful biomarkers for identifying and monitoring high-risk survivors.
author2 Lee Kong Chian School of Medicine (LKCMedicine)
author_facet Lee Kong Chian School of Medicine (LKCMedicine)
Fong, Siew-Wai
Goh, Yun Shan
Torres-Ruesta, Anthony
Chang, Zi Wei
Chan, Yi-Hao
Neo, Vanessa Kexin
Lee, Bernett
Duan, Kaibo
Amrun, Siti Naqiah
Yeo, Nicholas Kim-Wah
Chen, Hsiuyi V.
Tay, Matthew Zirui
Carissimo, Guillaume
Tan, Seow Yen
Leo, Yee Sin
Lye, David C.
Renia, Laurent
Young, Barnaby Edward
Ng, Lisa F. P.
format Article
author Fong, Siew-Wai
Goh, Yun Shan
Torres-Ruesta, Anthony
Chang, Zi Wei
Chan, Yi-Hao
Neo, Vanessa Kexin
Lee, Bernett
Duan, Kaibo
Amrun, Siti Naqiah
Yeo, Nicholas Kim-Wah
Chen, Hsiuyi V.
Tay, Matthew Zirui
Carissimo, Guillaume
Tan, Seow Yen
Leo, Yee Sin
Lye, David C.
Renia, Laurent
Young, Barnaby Edward
Ng, Lisa F. P.
author_sort Fong, Siew-Wai
title Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection
title_short Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection
title_full Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection
title_fullStr Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection
title_full_unstemmed Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection
title_sort prolonged inflammation in patients hospitalized for coronavirus disease 2019 (covid-19) resolves 2 years after infection
publishDate 2023
url https://hdl.handle.net/10356/172157
_version_ 1784855579671396352
spelling sg-ntu-dr.10356-1721572023-12-03T15:38:41Z Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection Fong, Siew-Wai Goh, Yun Shan Torres-Ruesta, Anthony Chang, Zi Wei Chan, Yi-Hao Neo, Vanessa Kexin Lee, Bernett Duan, Kaibo Amrun, Siti Naqiah Yeo, Nicholas Kim-Wah Chen, Hsiuyi V. Tay, Matthew Zirui Carissimo, Guillaume Tan, Seow Yen Leo, Yee Sin Lye, David C. Renia, Laurent Young, Barnaby Edward Ng, Lisa F. P. Lee Kong Chian School of Medicine (LKCMedicine) School of Biological Sciences Singapore Immunology Network, A*STAR National Centre for Infectious Diseases, Singapore Tan Tock Seng Hospital Yong Loo Lin School of Medicine, NUS A*STAR Infectious Diseases Labs Science::Medicine Biomarkers COVID Vaccine Long-term complications from coronavirus disease 2019 (COVID-19) are concerning, as survivors can develop subclinical multiorgan dysfunction. It is unknown if such complications are due to prolonged inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination may reduce sequela. We conducted a prospective longitudinal study on hospitalized patients over 24 months. Clinical symptoms were collected by self-reporting during follow-up, along with blood samples for quantification of inflammatory markers and immune cell frequencies. All patients were given one dose of mRNA vaccine at 12-16 months. Their immune profiles at 12 and 24 months were compared. Approximately 37% and 39% of our patients reported post-COVID-19 symptoms at 12 and 24 months, respectively. The proportion of symptomatic patients with more than one symptom decreased from 69% at 12 months to 56% at 24 months. Longitudinal cytokine profiling revealed a cluster of individuals with persistently high inflammatory cytokine levels 12 months after infection. Patients with prolonged inflammation showed elevated terminally differentiated memory T cells in their blood; 54% had symptoms at 12 months. The majority of inflammatory markers and dysregulated immune cells in vaccinated patients recovered to a healthy baseline at 24 months, even though symptoms persisted. Post-COVID-19 symptoms can linger for 2 years after the initial infection and are associated with prolonged inflammation. Prolonged inflammation in hospitalized patients resolves after 2 years. We define a set of analytes associated with persistent inflammation and presence of symptoms, which could be useful biomarkers for identifying and monitoring high-risk survivors. Agency for Science, Technology and Research (A*STAR) National Medical Research Council (NMRC) National Research Foundation (NRF) Published version This work was supported by A*STAR Infectious Diseases Labs core research grants and COVID‐19 (project number H20/04/g1/006) research grant provided to Singapore Immunology Network by the Biomedical Research Council (BMRC). This research was also funded by the National Medical Research Council (NMRC) COVID‐19Research fund (COVID19RF‐001, COVID19RF‐007, COVID19RF‐008, COVID19RF‐060, and OF‐LCG19May‐0034) and US Food and Drug Administration funding (#75F40120C00085). The SIgN Multiplex Analysis of Proteins (MAP) platform was supported by a grant from the National Research Foundation, Immunomonitoring Service Platform (ISP) (NRF2017_SISFP09) from the National Research Foundation Singapore (NRF). Y.S.G was supported by a Career Development Fund from A*STAR (SC35/22‐805100). 2023-11-27T05:39:18Z 2023-11-27T05:39:18Z 2023 Journal Article Fong, S., Goh, Y. S., Torres-Ruesta, A., Chang, Z. W., Chan, Y., Neo, V. K., Lee, B., Duan, K., Amrun, S. N., Yeo, N. K., Chen, H. V., Tay, M. Z., Carissimo, G., Tan, S. Y., Leo, Y. S., Lye, D. C., Renia, L., Young, B. E. & Ng, L. F. P. (2023). Prolonged inflammation in patients hospitalized for coronavirus disease 2019 (COVID-19) resolves 2 years after infection. Journal of Medical Virology, 95(5), e28774-. https://dx.doi.org/10.1002/jmv.28774 0146-6615 https://hdl.handle.net/10356/172157 10.1002/jmv.28774 37212320 2-s2.0-85160662533 5 95 e28774 en COVID19RF-001 COVID-19RF-007 COVID19RF-008 COVID19RF-060 OF‐LCG19May‐0034 NRF2017_SISFP09 H/20/04/g1/006 Journal of Medical Virology © 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. application/pdf